Health Datapalooza IV: June 3rd-4th, 2013 The State of the Art: Enterprise Data Use at the Point of Care Moderator: Janet Marchibroda, Director, Health Innovation Initiative, Bipartisan Policy Center The new delivery models have made it clear- they need health information technology (IT) and data in order to succeed in providing high value health care. Many decision-makers and clinical staff are overwhelmed by or are looking for the evidence to support using the increasing amount and divergent types of data that can be leveraged at the enterprise level and point of care. Patient-generated data, open data streams, cost and quality information – how will it fit into the clinical workflow, and does it make a difference in operations and clinical outcomes? Join us for demos and a discussion of the state of the art. Panel A (3:30-4:15pm): Enterprise-Level Data Analytics Speakers: Jack Challis, Chief Executive Officer & Co-Founder, CliniCast Allen Kamer, Vice President Corporate Development and Marketing, Humedica Jonathan Porter, Vice President Product Strategy, athenahealth Eric Page, Chief Executive Officer, Amplify Health Graham Gardner, Chief Executive Officer, Kyru.us Panel B (4:15-5:00 pm): Data at the Point of Care Speakers: Jason Bhan, Executive Vice President & Co-founder, Medivo Madhu Nutakki, Vice President of Digital Presence Technologies, Kaiser Permanente Noah Craft, Chief Medical Officer, VisualDx Michael Long, Chief Executive Officer, Lumeris Omri Gottesman, CLIPMERGE, Mount Sinai School of Medicine These sessions are eligible for continuing education credit.

1. Borrowed from ‘Controversies in Medicine: Direct-to-Consumer Genetic Testing’
By Geoffrey S. Ginsburg, MD, PhD. DukeMed Magazine, June 18, 2010.
Personalizing Medicine at the Point of Care:
Learning to Walk Before we Run

2. Disclosures
Patent Applications:
System and Methods for Personalized Clinical Decision Support

9. CLIPMERGE
Clinical Implementation of Personalized Medicine through Electronic Health Records and Genomics

10. CLIPMERGE: What it is
• Genome-guided Clinical Decision Support delivered
through the EHR
• Data management platform enables personalized
medicine at the point of care
• Focus of research program is providers
• CLIPMERGE PGx pilot currently enrolling patients

11. Why Pharmacogenomics (PGx)?
• Using a genetic profile to predict response to drugs
• FDA has modified labels to include PGx information
• Peer-reviewed guidelines published

12. CLIPMERGE PGx: How it works 1
• 1500 Mount Sinai patients
• Pre-emptively genotyped for PGx variants
• CDS for clopidogrel, warfarin and simvastatin
• Providers surveyed and data collected directly from EHR
• Rules exist in the CLIPMERGE engine like this:
Drug ‘A’ + Genotype 2 = DANGER!

13. Gottesman et al. The CLIPMERGE PGx Program: Clinical Implementation of Personalized Medicine Through Electronic Health
Records and Genomics-Pharmacogenomics. Clin Pharmacol Ther. 2013 Apr 3. doi: 10.1038/clpt.2013.72.
CLIPMERGE PGx: How it works 2

14. CLIPMERGE PGx Team
Angelika Ludtke, MD, PhD
Steve Ellis
Casey Lynnette Overby, PhD
Jean Sebastien-Hulot, MD, PhD
Noura Abul-Husn, MD, PhD
Rajiv Nadukuru
Vaneet Lotay
Jeffrey Hall
Brian Cajes
Naresh Hinduja
Deepesh Chandra
Prabhakaran Natarajan
Bei Zhang
May Liu
Epic Team
Kristin Myers
Joseph Kannry, MD
Kevin Delaney
Aditi Vakil
Riya Deepak
Elizabeth Kerch
Noel Howard
Paul Francaviglia
Karen Trommer
Jason Martin
Daniel Edonyabo
Daniel Katselnik
Research IT
Bill Fultz
Eugene Gershteyn
Vlad Metelkin
IPM Team
Erwin Bottinger, MD
Yolanda Keppel
Ana Mejia
Tanisha Brown
Stacy Paris
Quingbin Song, MD
Ilkka Huopaniemi
Bernadette Liggayu
Patrick Shanley
Yumin Li
MS Statistical Support
Emilia Bagiella, PhD
DOM
Barbara Murphy, MD
Alex Federman, MD
Scott Lorin MD
Jenny Lin, MD
Eva Waite, MD
Juan Wisnivesky, MD
AIG Team
Amol Kulkarni
Omair Haq
Anand Ramaswamy
Robert Kitchen
Infrastructure Team
Larry Bloom
Li Liao
Henry Escobar
Genetics and Genomic Sciences
Stuart Scott, PhD
Rajasekar R-Chakravarthi